Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Exploring and Validating Biomarkers in Menstrual Blood (MB1)

4 juin 2026 mis à jour par: Genie Fertility Ltd

This study aims to find out whether menstrual blood can provide similar useful biological information to a standard blood sample taken from a vein in the arm as well as uterine biopsies and vaginal swabs.

Menstrual and reproductive health have historically been under-represented in research, and menstrual blood remains an under-studied biological sample despite its potential value for understanding women's health.

Women aged 18 years and over who are currently menstruating may be invited to take part. Participants will attend a study visit during their menstrual period, where they will provide a menstrual blood sample collected using a menstrual cup and a small blood sample from a vein in the arm.The samples will be sent to a research laboratory and analysed to compare the biological information they contain.

Some samples may also be processed to extract DNA and isolate cells for research purposes.

The study is low risk and is not expected to provide a direct medical benefit to participants. However, it may help improve understanding of whether menstrual blood could be used more widely in future women's health and fertility research. Participants will not receive individual results, as the tests are for research purposes only and are not designed to provide clinical information about their health.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Description détaillée

The main aim of this study is to find out whether menstrual blood collected using a menstrual cup can provide similar useful biological information to a standard blood sample taken from a vein in the arm as well as self-administered vaginal swabs and uterine biopsies.The secondary aims of the study are to assess how practical and acceptable it is to collect menstrual blood in a clinic setting, whether these samples can be processed reliably in the laboratory, and whether menstrual blood contains similar useful biological information to a standard blood sample.Menstrual blood is an under-studied biological sample that may contain useful information about reproductive health and general biological processes. At present, standard blood samples are commonly used in research, additionally vaginal swabs and uterine biopsies are invasive techniques but menstrual blood may provide similar or additional information in a less invasive and more relevant way for some aspects of women's health.

There is currently limited evidence on whether menstrual blood can be collected, processed and analysed reliably for this purpose. This study is therefore needed to assess whether menstrual blood could be used alongside or in some cases instead of standard blood sampling in future women's health research.This is a multi-centre observational research study involving women aged 18 years and over who are currently menstruating. Participants will be recruited through participating fertility clinics.

Potential participants will be provided with a Participant Information Sheet and given time to consider participation.

Those who agree to take part will provide written informed consent before any study procedures are carried out.

Participants will attend a study visit during menstruation. At this visit, a trained member of staff will collect a small blood sample from a vein in the arm, this is part of a standard routine care blood draw. Participants will also provide a menstrual blood sample collected using a menstrual cup and a self administered vaginal swab All samples will be labelled with a unique study code and transferred to the research laboratory for processing and analysis. The study will compare information obtained from menstrual blood and standard blood samples to assess whether menstrual blood can be used as a useful biological sample for research. Some samples may be analysed immediately, while others may be stored temporarily as part of this ethically approved study. Samples will also undergo DNA extraction and cell isolation for research purposes.

There are no follow-up visits planned as part of this study, and participants will not receive individual test results.

Participation ends once the study samples have been collected. However some follow up appointments may be required for example if insufficient sample is obtained first time.

Type d'étude

Observationnel

Inscription (Estimé)

100

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Women who have been through menarche and are considering fertility treatment, and menstruate without debilitating gynecological conditions

La description

Inclusion Criteria:Are female and aged 18 years or over Experienced menarche but not menopause Are willing and able to provide a menstrual blood sample collected using a menstrual cup Are willing to provide a self-administered vaginal swab Are willing and able to undergo collection of a peripheral venous blood sample Are able to understand the study procedures and requirements Are able and willing to provide written informed consent Are willing for their samples and associated study data to be used for the research purposes described in the study documentation Participants may be recruited from participating fertility clinics.

-

Exclusion Criteria:

  • Are male or 17 years or younger Not experienced menarche or experienced menopause Currently pregnant Have an active vaginal, pelvic or systemic infection that may affect safe participation or sample integrity

Have a known allergy, sensitivity or intolerance to the menstrual cup material Have any medical, anatomical or physical condition that would make use of a menstrual cup unsafe or impractical Have any condition which, in the opinion of the investigator or delegated clinician, would make participation unsafe, inappropriate or unsuitable Are unable or unwilling to provide written informed consent

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
People with no fertility isssues
People such as egg donors, frozen egg patients who are doing IVF without having had any fertility issues
People with fertility issues
People with infertility

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Pregnancy percentage
Délai: 2 months
The pregnancy result of a patient after IVF treatment, and percentage of patients who become pregnant
2 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Live birth
Délai: 10 months
the live birth, or other result of the patients' pregnancy
10 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 juillet 2026

Achèvement primaire (Estimé)

30 avril 2029

Achèvement de l'étude (Estimé)

30 avril 2029

Dates d'inscription aux études

Première soumission

26 mai 2026

Première soumission répondant aux critères de contrôle qualité

4 juin 2026

Première publication (Réel)

10 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 1 (Mobile Health and Wellness Program)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner